On March 22, 2013, IP Osgoode and the Canadian Intellectual Property Office (CIPO) co-hosted a conference examining the role of student researchers in commercializing intellectual property. Inspired by her SSHRC-funded…
Tag: sean jackson
The Teva Experience: A Semester in Osgoode's IP Intensive Program
As part of Osgoode’s Intellectual Property Law Intensive Program, I had the opportunity to spend ten weeks at Teva Canada working with in-house counsel. Teva Canada is one of Canada’s largest generic pharmaceutical…
Subsequent Entry Biologic Litigation Set to Take Off in Canada
The Canadian pharmaceutical industry is entering a new era as Subsequent Entry Biologic (SEB) litigation begins to emerge in the Canadian pharmaceutical landscape. Biologic drugs are derived through the metabolic…
Canada’s Top Court Gives Canadians Something to Get Excited About, Generic Viagra!
On November 8, 2012 the Supreme Court of Canada (SCC) released its eagerly anticipated decision in the “Viagra Appeal”. In a unanimous decision written by Justice LeBel, the SCC found…
Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada
This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the world. The pill is of…
in Access to Medicines, European Union, Feature Post, IP, Patents, Pharmaceutical Drugs2by Editor
3133
Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So...
The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (CETA). A key issue has been ensuring that Canadian intellectual property rights for pharmaceutical…